SOURCE: Streetwise Reports

Streetwise Reports

June 01, 2015 07:02 ET

RXi Pharmaceuticals' CEO Dr. Geert Cauwenbergh Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - Jun 1, 2015) - Inhibition -- developing therapies that can suppress certain disease mechanisms -- is a major thrust in modern biotech. With its unique RNA interference delivery platform, spun out from the mind of a Nobel laureate, CEO Dr. Geert Cauwenbergh tells The Life Sciences Report about the transformational treatments RXi Pharmaceuticals Corporation (NASDAQ: RXII) has in the pipeline, therapies that can both enrich lives and investors' portfolios.

The Life Sciences Report: What is the focus of your company, RXi Pharmaceuticals Corporation?

Geert Cauwenbergh: The major focus of our company is development of therapeutics based on a proprietary platform of RNAi -- RNA interference -- as a way to reduce the level of upregulated proteins that play a role in disease. The areas that we have selected to work in at this point are dermatology and ophthalmology.

We own our self-delivering RNAi platform, and we are actively working to develop that into transformational treatments that can be used in these two areas. We also will provide licenses to other biotech companies that are interested in using our technology platform for developments in their therapeutic areas of interest.

In addition to the interference RNA technology, we have a topical immunotherapy agent that can also be used in diseases that are poorly covered, like cutaneous metastases of malignant melanoma, or for the treatment for alopecia areata (hair loss caused by an autoimmune disorder), for which there is no treatment available today...

Continue reading this interview with Dr. Geert Cauwenbergh: It's All in the Delivery: How RXi Pharmaceuticals' Innovative Platform Will Transform Medicine.

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.


RXi Pharmaceuticals Corporation paid The Life Sciences Report to conduct, produce and distribute the interview. Geert Cauwenbergh had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Geert Cauwenbergh and not of The Life Sciences Report or its officers.

Contact Information